Furthermore, the launch and European release of the Evolut TAVR system in mid-2020 demonstrated Medtronic’s continued commitment to innovation. The company's consistent dividend payouts ...

Medtronic has reported late-breaking data from the randomised Evolut Low Risk Trial’s five-year outcomes of the Evolut transcatheter aortic valve replacement (TAVR) system in low-risk aortic ...

GALWAY, Ireland and CHICAGO, March 30, 2025 /PRNewswire/ -- Medtronic plc (NYSE ... transcatheter aortic valve replacement (TAVR) system delivers a numerically lower rate of all-cause mortality ...